Shared Decision-making Process for Unprovoked vEnous THromboEmbolism Management. (ETHER )

If you've had a blood clot, also known as a venous thromboembolism (VTE), you'll know how serious it can be. This can include deep vein thrombosis (DVT), a clot usually in your leg, or pulmonary embolism (PE), a clot that travels to your lungs. While blood thinners (anticoagulants) are very effective at reducing the risk of another clot and saving lives, they also carry a risk of bleeding, which can sometimes be severe. This can make deciding how long to stay on these medications quite tricky.

For many people, a blood clot happens because of something specific, like having major surgery or being unable to move for a long time. In these cases, treatment often lasts for about three months. However, for more than half of people, a blood clot happens 'out of the blue' – doctors call this 'unprovoked' VTE. If you've had an unprovoked VTE, there's a higher chance of it happening again. Because of this, current advice often suggests taking blood thinners indefinitely.

But taking blood thinners long-term means a continued risk of bleeding. This study wants to find a better way to balance the risk of another clot against the risk of bleeding. The ETHER study is testing a new way for doctors and patients to work together to make this important decision. They will use special tools that combine your personal risk factors with an understanding of your experiences to help decide the best length of time for your blood thinner treatment. The hope is that this shared decision-making approach will lead to better outcomes, fewer complications, and happier patients.